ABOUT US

Our Company

Glycotest is developing unique and non-invasive blood tests for the large populations at risk of developing liver cancers and fibrosis-cirrhosis. Our proprietary technology could revolutionize care and treatment for groups at risk due to chronic liver disease-both people with viral hepatitis (chronic hepatitis B and C infections) and the rapidly growing population with non-viral hepatitis (NASH) due to obesity and metabolic disease. Over 25 million people in the U.S., 800 million worldwide, and another 1.2 billion in jeopardy due to fatty liver disease (NAFLD) may benefit from Glycotest’s products.

Background

Glycotest was created in 2012 based on technology developed by two experts in the fields of liver disease and glycobiology-Professors Timothy Block and Anand Mehta at Drexel University College of Medicine and the Baruch S. Blumberg Institute. Glycotest has the exclusive worldwide rights to the use of over 50 patented serum glycoprotein biomarkers whose sugar structures are altered in liver cancers and fibrosis-cirrhosis by the abnormal attachment of the monosaccharide fucose.

First Test–HCC Panel for Early Detection

Our first test is the HCC Panel which is designed for the early detection of Hepatocellular Carcinoma (HCC). The HCC Panel is a surveillance test for patients who have had chronic liver disease and are at a higher risk of getting HCC. If HCC is detected early, it can be curable, but unfortunately, current test methods are not sensitive enough to catch most early-stage HCC. The HCC Panel test is currently being used in a 476 patient clinical validation study which we expect will be completed in mid-2020. We are planning to launch the HCC Panel to hepatologists late next year through our CLIA lab.

OUR TEAM

MANAGEMENT TEAM

  • Charles Swindell

    Charles Swindell has over 30 years of experience in biopharmaceutical R&D, product development, and senior management in entrepreneurial life science companies.   He has been head of R&D at two companies, one in which he led the team during advancement of an oncology product into Phase III clinical development and was part of the senior [...]

BOARD OF DIRECTORS

  • Professor Stephen Smith

    Professor Stephen Smith, Non-Executive Director, joined the NetScientific Board in 2016. Stephen has held senior leadership roles in the NHS and academia. He has had a long and distinguished career as a clinician scientist, Head of Department, Dean and CEO. His name is associated with the Medical Research Council, University of Cambridge, Imperial College, London [...]
  • Ilian Iliev PhD

    Dr. Ilian Iliev joined the Net Scientific Board in 2019 and became CEO in 2020. He is also Managing Director of EMV Capital (EMVC) where he also leads the investment advisory team. Ilian spun-out EMV Capital out of EcoMachines Ventures, which was founded in 2013. Prior to that he co-founded and was CEO of CambridgeIP [...]
  • Mr Yuejian ZHANG

    Mr Yuejian ZHANG graduated with Ph.D. degree of Immunology from Fudan University in 2000. He joined Shanghai Fosun Pharmaceutical (Group) Co. Ltd. since Sep 2000 till recent. During the period, he had served as Research Scientist and Director of Research and Development during Sep 2000 to Feb 2002; Vice General Manager, Director of Business Development [...]
  • Mr Jing YU

    Mr Jing YU holds a Ph.D. degree of Pharmaco-economy. He had served as researcher for various national medical and healthcare institutes and organizations during the education and career in France during 2005 to 2011. He had served as General Manager for Dynasty Biotech Co., Ltd (subsidiary of Shanghai New Summit Pharmaceutical Group) during 2012 to [...]

SCIENTIFIC AND MEDICAL ADVISORS

  • Timothy Block, PhD, Innovator and Advisor

    Dr. Block is Co-Founder and President of the Baruch S. Blumberg Institute and the Hepatitis B Foundation, which established the Institute in 2003 to advance its research mission to find a cure for hepatitis B. He has been involved in hepatitis research for more than 25 years and is internationally recognized for his scholarship and [...]
  • Anand Mehta, DPhil, Innovator, Advisor, Member, Medical Advisory Board

    Dr. Mehta is SmartState Endowed Chair of Proteomic Biomarkers and Professor, Medical University of South Carolina. He received his graduate degree in Biochemistry from the University of Oxford under the supervision of Professor Raymond Dwek and Noble Laureate Baruch Blumberg. While a student at the University of Oxford, Dr. Mehta examined methods by which viruses [...]
  • David Chernoff, MD, Chair, Medical Advisory Board

    Dr. Chernoff has served as acting Chief Medical Officer for several start-up molecular diagnostic companies including XDx, CardioDx, and Tethys Bioscience. Previously, he was Vice President of Corporate Technology at Elan Pharmaceuticals and Medical Director of Chiron Diagnostics, where he played a pivotal role in the development of assays for HIV, HCV, HBV, and CMV. [...]
  • Scott Friedman, MD, Member, Medical Advisory Board

    Scott Friedman is Chief of the Division of Liver Diseases and Dean for Therapeutic Discovery at the Icahn School of Medicine at Mount Sinai, New York and was President of the American Association for the Study of Liver Diseases (AASLD) in 2009. Dr. Friedman is one of the foremost leaders in the field of liver [...]
  • Douglas Dieterich, MD, Member, Medical Advisory Board

    Douglas Dieterich is Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York with appointments in the Divisions of Liver Diseases, Gastroenterology and Infectious Diseases, and is the newly appointed Director for the Institute for Liver Medicine at the Mount Sinai Health System. Chronic hepatitis B and C are key focal [...]

INVESTORS

NetScientific UK Ltd.

About NetScientific UK Ltd.

About NetScientific UK Ltd.

NetScientific identifies, develops and commercializes transformative biomedical and healthcare technologies originating from leading universities, teaching hospitals and research institutes, with a focus on United Kingdom and United States.

More information about NetScientific’s purpose, core strategy and investment model are available at netscientific.net.

Fosun Pharma

About Fosun Pharma

About Fosun Pharma

Established in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a leading healthcare group in the PRC. Adhering to the mission of improving human health, Fosun Pharma’s business covers all key sectors of the healthcare industry chain, including pharmaceutical manufacturing and R&D, healthcare services, medical devices, and medical diagnosis, as well as pharmaceutical distribution and retail. Fosun Pharma always regards innovation as the driving force for its business growth.

More information about Fosun Pharma click: https://www.fosunpharma.com

GLYCOTEST PRESENTATION

A New Paradigm for Early Diagnosis and Surveillance For Liver Cancer

ABOUT US | Glycotest Diagnostics